http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017214299-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9cc0863fc17e63625be5f5e3c9d2b8a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6957 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 |
| filingDate | 2017-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1e362d19d27630a2c9c5e63799413c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_134d63691634b462d713606ab10f9301 |
| publicationDate | 2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017214299-A1 |
| titleOfInvention | NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS |
| abstract | Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin αvβ3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity. Utility of the compositions disclosed may treat angiogenesis-mediated disorders such as Cancer (Solid tumors and Liquid tumors), ocular disorders (Diabetic Retinopathy and Age-related Macular Degeneration), inflammatory disorders (arthritis, osteoarthritis), atherosclerosis, lesions, and dermatology (Rosacea, Psoriasis, skin cancer) and diseases mediated or dependent upon the generation of new blood cells via angiogenesis to persist and the treatment thereof or dependent on antagonizing the formation of new blood vessels to slow or eliminate angiogenic pathways. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023181501-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11723888-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10201616-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10695436-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077082-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351137-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10961204-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11186551-B2 |
| priorityDate | 2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.